organophosphonates has been researched along with Liver Steatosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koeberl, DD; Lian, B; Liao, XH; Lim, A; Masamune, H; Refetoff, S; Tran, B; Waskowicz, LR; Yen, PM; Zhou, J | 1 |
| Chan, SH; Chang, TT; Cheng, PN; Huang, W; Lin, YJ; Su, IJ; Tsai, HW; Wu, HC; Wu, IC; Yen, CJ | 1 |
| Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
| Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C | 1 |
| Maier, KP | 1 |
2 review(s) available for organophosphonates and Liver Steatosis
| Article | Year |
|---|---|
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
[Drug therapy in chronic liver disease].
Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Sclerosing; Chronic Disease; Drug Therapy, Combination; Fatty Liver; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Hepatolenticular Degeneration; Humans; Immunosuppression Therapy; Interferons; Lamivudine; Liver Cirrhosis, Biliary; Liver Diseases; Organophosphonates; Prednisolone; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ribavirin; Time Factors | 2005 |
3 other study(ies) available for organophosphonates and Liver Steatosis
| Article | Year |
|---|---|
A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Topics: Animals; Autophagy; Disease Models, Animal; Fatty Acids; Fatty Liver; Glucose-6-Phosphatase; Glycogen; Glycogen Storage Disease Type I; Liver; Mice; Mice, Knockout; Mitochondria, Liver; Organelle Biogenesis; Organophosphonates; Oxidation-Reduction; Thyroid Hormone Receptors beta; Triglycerides | 2019 |
Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; DNA, Circular; Drug Resistance, Viral; Fatty Liver; Female; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Lamivudine; Liver; Liver Neoplasms; Male; Middle Aged; Necrosis; Organophosphonates; Protein Precursors; Sequence Deletion; Viral Load; Young Adult | 2016 |
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hepatitis C; HIV Infections; Humans; Liver; Male; Multivariate Analysis; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2013 |